"","title","geo_accession","status","submission_date","last_update_date","type","channel_count","source_name_ch1","organism_ch1","characteristics_ch1","treatment_protocol_ch1","growth_protocol_ch1","molecule_ch1","extract_protocol_ch1","label_ch1","label_protocol_ch1","taxid_ch1","hyb_protocol","scan_protocol","description","data_processing","platform_id","contact_name","contact_department","contact_institute","contact_address","contact_city","contact_state","contact_zip/postal_code","contact_country","supplementary_file","data_row_count","disease:ch1"
"GSM2461411","CSF_day0_ptcontrol","GSM2461411","Public on Feb 01 2018","Jan 18 2017","Feb 01 2018","RNA","1","CSF from control pt","Homo sapiens","disease: control patient","Exosomes were isolated from 500 μL of plasma and 1 mL of CSF, and total RNA was isolated from exosome samples","The blood and CSF samples on day 3 were sampled from two SAH patients. Sample from non-SAH patient was used as control sample.","total RNA","RNA samples were extracted from CSF and blood using 3D-Gene extraction reagent from liquid sample(Toray Industries Inc., Tokyo, Japan).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","CSFCON","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","New Projects Development Division","Toray Industries,Inc.","Tebiro 6-10-1","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2461nnn/GSM2461411/suppl/GSM2461411_SH51D52_2.txt.gz","2565","control patient"
"GSM2461412","CSF_day3_pt1","GSM2461412","Public on Feb 01 2018","Jan 18 2017","Feb 01 2018","RNA","1","CSF from SAH pt1","Homo sapiens","disease: SAH patient","Exosomes were isolated from 500 μL of plasma and 1 mL of CSF, and total RNA was isolated from exosome samples","The blood and CSF samples on day 3 were sampled from two SAH patients. Sample from non-SAH patient was used as control sample.","total RNA","RNA samples were extracted from CSF and blood using 3D-Gene extraction reagent from liquid sample(Toray Industries Inc., Tokyo, Japan).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","CSFSAH1","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","New Projects Development Division","Toray Industries,Inc.","Tebiro 6-10-1","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2461nnn/GSM2461412/suppl/GSM2461412_SH51D52_3.txt.gz","2565","SAH patient"
"GSM2461413","CSF_day3_pt2","GSM2461413","Public on Feb 01 2018","Jan 18 2017","Feb 01 2018","RNA","1","CSF from SAH pt2","Homo sapiens","disease: SAH patient","Exosomes were isolated from 500 μL of plasma and 1 mL of CSF, and total RNA was isolated from exosome samples","The blood and CSF samples on day 3 were sampled from two SAH patients. Sample from non-SAH patient was used as control sample.","total RNA","RNA samples were extracted from CSF and blood using 3D-Gene extraction reagent from liquid sample(Toray Industries Inc., Tokyo, Japan).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","CSFSAH2","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","New Projects Development Division","Toray Industries,Inc.","Tebiro 6-10-1","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2461nnn/GSM2461413/suppl/GSM2461413_SH51D52_4.txt.gz","2565","SAH patient"
"GSM2461414","Blood _day0_ptcontrol","GSM2461414","Public on Feb 01 2018","Jan 18 2017","Feb 01 2018","RNA","1","Blood from control pt","Homo sapiens","disease: control patient","Exosomes were isolated from 500 μL of plasma and 1 mL of CSF, and total RNA was isolated from exosome samples","The blood and CSF samples on day 3 were sampled from two SAH patients. Sample from non-SAH patient was used as control sample.","total RNA","RNA samples were extracted from CSF and blood using 3D-Gene extraction reagent from liquid sample(Toray Industries Inc., Tokyo, Japan).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","BloodCON","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","New Projects Development Division","Toray Industries,Inc.","Tebiro 6-10-1","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2461nnn/GSM2461414/suppl/GSM2461414_SH51D54_2.txt.gz","2565","control patient"
"GSM2461415","Blood _day3_pt1","GSM2461415","Public on Feb 01 2018","Jan 18 2017","Feb 01 2018","RNA","1","Blood from SAH pt1","Homo sapiens","disease: SAH patient","Exosomes were isolated from 500 μL of plasma and 1 mL of CSF, and total RNA was isolated from exosome samples","The blood and CSF samples on day 3 were sampled from two SAH patients. Sample from non-SAH patient was used as control sample.","total RNA","RNA samples were extracted from CSF and blood using 3D-Gene extraction reagent from liquid sample(Toray Industries Inc., Tokyo, Japan).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","BloodSAH1","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","New Projects Development Division","Toray Industries,Inc.","Tebiro 6-10-1","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2461nnn/GSM2461415/suppl/GSM2461415_SH51D54_3.txt.gz","2565","SAH patient"
"GSM2461416","Blood _day3_pt2","GSM2461416","Public on Feb 01 2018","Jan 18 2017","Feb 01 2018","RNA","1","Blood from SAH pt2","Homo sapiens","disease: SAH patient","Exosomes were isolated from 500 μL of plasma and 1 mL of CSF, and total RNA was isolated from exosome samples","The blood and CSF samples on day 3 were sampled from two SAH patients. Sample from non-SAH patient was used as control sample.","total RNA","RNA samples were extracted from CSF and blood using 3D-Gene extraction reagent from liquid sample(Toray Industries Inc., Tokyo, Japan).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","BloodSAH2","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","New Projects Development Division","Toray Industries,Inc.","Tebiro 6-10-1","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2461nnn/GSM2461416/suppl/GSM2461416_SH51D54_4.txt.gz","2565","SAH patient"
